1. Volume 1, Issue 1, Pages 23-36 (June 2015)
Two randomized controlled trials of SB in mild-to-moderate Alzheimer's disease 
Gareth Maher-Edwards, Carolyn Watson, John Ascher, Carly Barnett, Diane Boswell, John Davies, Manuel Fernandez, Alexander Kurz, Orazio Zanetti, Beth Safirstein, Juan Paul Schronen, Marina Zvartau-Hind, Michael Gold 
Alzheimer's & Dementia: Translational Research & Clinical Interventions 
Volume 1, Issue 1, Pages (June 2015)
DOI: /j.trci
Copyright © 2015 GlaxoSmithKline Terms and Conditions

2. Fig. 1
Flow of subjects through Study 1 (A) and Study 2 (B). ITT, intent-to-treat.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2015 1, 23-36DOI: ( /j.trci )
Copyright © 2015 GlaxoSmithKline Terms and Conditions

3. Fig. 2
Results from analysis of change from baseline using a MMRM model in the assessment of treatment effect of SB on the ADAS-Cog (A, B), CIBIC+ (C), CDR-SB (D), ADCS-ADL (E, F), and RBANS (G, H) in the ITT population of Study 1 (panels A, C, E, G) and 2 (panels B, D, F, H). Data presented as adjusted mean ± 95% CI. Abbreviations: MMRM, mixed model for repeated measures; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; CDR-SB, Clinical Dementia Rating-Sum of Boxes; CI, confidence interval; CIBIC+, Clinician Interview-Based Impression of Change Plus Caregiver Input; ADCS-ADL, Alzheimer's Disease Co-operative Study-Activities of Daily Living Scale; RBANS, Repeatable Battery for Assessment of Neuropsychological Status; ITT, intent-to-treat.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2015 1, 23-36DOI: ( /j.trci )
Copyright © 2015 GlaxoSmithKline Terms and Conditions